Literature DB >> 3397970

Antimalarial drugs, systemic lupus erythematosus and pregnancy.

A L Parke1.   

Abstract

Antimalarial drugs containing the 4-amino quinoline radical are used to help control disease activity in discoid lupus erythematosus and systemic lupus erythematosus (SLE). Many patients with these complaints are young women, some of whom will become pregnant. The use of these substituted 4-amino quinoline compounds in pregnancy is controversial. We studied the full obstetric histories of 8 women with SLE who had taken either chloroquine phosphate or hydroxychloroquine sulphate (Plaquenil) throughout the entire length of at least 1 pregnancy. These 8 women had 14 pregnancies while receiving antimalarial drugs. Fetal wastage was high in these patients, regardless of antimalarial therapy, and was almost 100% in patients who were clinically active. Six normal full term spontaneous deliveries resulted from these pregnancies with clinically healthy normal babies born despite exposure to antimalarial therapy throughout the pregnancies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3397970

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

2.  Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.

Authors:  N M Buchanan; E Toubi; M A Khamashta; F Lima; S Kerslake; G R Hughes
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

Review 3.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 4.  The Hopkins Lupus Pregnancy Center: ten key issues in management.

Authors:  Michelle Petri
Journal:  Rheum Dis Clin North Am       Date:  2007-05       Impact factor: 2.670

Review 5.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

6.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

Review 7.  Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

Authors:  Christina D Chambers; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models.

Authors:  Rodrigo Delvecchio; Luiza M Higa; Paula Pezzuto; Ana Luiza Valadão; Patrícia P Garcez; Fábio L Monteiro; Erick C Loiola; André A Dias; Fábio J M Silva; Matthew T Aliota; Elizabeth A Caine; Jorge E Osorio; Maria Bellio; David H O'Connor; Stevens Rehen; Renato Santana de Aguiar; Andrea Savarino; Loraine Campanati; Amilcar Tanuri
Journal:  Viruses       Date:  2016-11-29       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.